Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study

Journal of Neurology

Volumn 263, Issue 7, 2016, Pages 1287-1295

  Havrdová, Eva ^a   Belova, Anna ^b   Goloborodko, Alla ^c   Tisserant, Anne ^d   Wright, Andrew ^d   Wallstroem, Erik ^d   Garren, Hideki ^d   Maguire, Ralph Paul ^d   Johns, Donald R ^d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b PRIVOLZHSKY RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^c Department of Obstetrics and Gynecology   (Ukraine)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Clinical trial; MRI; Multiple sclerosis; Secukinumab

Indexed keywords

BETA DEFENSIN 2; GADOLINIUM; INTERLEUKIN 17; PLACEBO; SECUKINUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ADVERSE OUTCOME; ARTICLE; BRAIN DAMAGE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INFESTATION; INJURY; INTOXICATION; MALE; MENTAL DISEASE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; VASCULAR DISEASE; ADOLESCENT; BRAIN; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISABILITY; DRUG EFFECTS; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BRAIN; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84965036792     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-016-8128-x     Document Type: Article

References (13)

1. Tzartos JS, Friese MA, Craner MJ et al (2008) Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172:146–155
2. Caccamo N, La Mendola C, Orlando V et al (2011) Differentiation, phenotype, and function of interleukin-17-producing human Vγ9 Vδ2 T cells. Blood 118:129–138
3. Bălaşa R, Bajko Z, Huţanu A (2013) Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β. Mult Scler 19:885–890
4. Yan Y, Ding X, Li K et al (2012) CNS-specific therapy for ongoing EAE by silencing IL-17 pathway in astrocytes. Mol Ther 20:1338–1348
5. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH, Ustekinumab MS Investigators (2008) Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 7:796–804
6. Vollmer TL, Wynn DR, Alam MS, Valdes J (2011) A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Mult Scler 17:181–191
7. Langley RG, Elewski BE, Lebwohl M et al, ERASURE Study Group; FIXTURE Study Group (2014) Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 371:326-338
8. Genovese MC, Durez P, Richards HB et al (2013) Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 72:863–869
9. McInnes IB, Sieper J, Braun J et al (2014) Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 73:349–356
10. Baeten D, Baraliakos X, Braun J et al (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382:1705–1713
11. Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846
12. Havrdova E, Belova A, Goloborodko A et al (2013) Sensitivity analysis of a phase IIa study of secukinumab in relapsing remitting multiple sclerosis. Mult Scler J 19:210–211 (poster number P520)
13. Jansen PA, Rodijk-Olthuis D, Hollox EJ et al (2009) Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One 4:e4725